onda di riempimento trans-mitralico telediastolico al Doppler pulsato; A’, velocità

telediastolica (sistole atriale) al TDI anulare mitralico; AcT, tempo di accelerazione del flusso polmonare; CI, cardiac index; CO, cardiac output; DT, deceleration time; E, onda di riempimento trans-mitralico protodiastolico al Doppler pulsato; E/A, rapporto E/A; E/E’, rapporto E/onda protodiastolica al TDI anulare mitralico; E’, velocità proto- diastolica al TDI anulare mitralico; EDD, left ventricular end-diastolic diameter;

EDDi, indexed left ventricular end-diastolic diameter; EDV, left ventricular end-

diastolic volume; EDVi, indexed left ventricular end-diastolic volume; EF, ejection fraction; ESD, left ventricular end-systolic diameter; ESDi, indexed left ventricular end-systolic diameter; ESVi, indexed left ventricular end-systolic volume; FS, fractional shortening; GLS, global longitudinal starin; IVSd, inter-ventricular septum diatsole; LAD, left atrial dimension; LAV, left atrial volume; LAVi, indexed left atrial volume; LVM, left ventricular mass; LVMi, indexed left ventricular mass; LVOT, left ventricular outflow tract; PWd, diastolic posterior wall; RVOT, right vetricular outflow tract; RWT, relative wall thickness; mPAP, mean pulmonary arterial pressure;

S’, velocità sistolica al TDI anulare mitralico; sPAP, systolic pulmonary arterial

pressure; SV, stroke volume; TAPSE, tricuspid annular plane systolic excursion;

Tabella E. Parametri emodinamici del decorso intra e post-operatorio, ottenuti mediante posizionamento di catetere di Swan-Ganz nei pazienti sottoposti a trapianti di fegato

PARAMETRO SIGLA FASE PRE-

ANEPATICA

FASE ANEPATICA

FASE POST- RIPERFUSIONE

Mean  SD Mean  SD Mean  SD

Pressione arteriosa media (mmHg) MAP 86.615  11.5725 90.692  12.3449 80.846  13.2467 Pressione venosa centrale (mmHg) PVC/R AP 11.308  1.9315 11.923  2.9000 12.692  3.4493 Pressione di occlusione polmonare (mmHg) PAOP/ PCWP 12.692  3.1460 15.615  3.5482 16.077  5.0243 Pressione arteriosa polmonare (mmHg) PAP 18.462  3.7553 20.154  3.1845 23.308  4.6972 Gittata cardiaca (l/m) CO 6.469  1.5887 6.485  1.2185 8.377  1.8820 Indice cardiaco (l/m/m2) CI 3.592  1.0185 3.523  0.6180 4.523  1.663 Resistenze vascolari polmonari (dynes x s x cm- 5) PVR 76.000  30.6295 47.231  23.3743 58.154  31. 5247

7. BIBLIOGRAFIA

1. Gassanov, N., et al., Cirrhotic cardiomyopathy: a cardiologist's perspective. World J Gastroenterol, 2014. 20(42): p. 15492-8.

2. Kowalski, H.J. and W.H. Abelmann, The cardiac output at rest in Laennec's cirrhosis. J Clin Invest, 1953. 32(10): p. 1025-33.

3. Lee, S.S., Cardiac abnormalities in liver cirrhosis. Western Journal of Medicine, 1989. 151(5): p. 530-535.

4. Chayanupatkul, M. and S. Liangpunsakul, Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int, 2014. 8(3): p. 308-15.

5. Zardi, E.M., et al., Cirrhotic cardiomyopathy. J Am Coll Cardiol, 2010. 56(7): p. 539-49.

6. Pudil, R., et al., Heart failure in patients with liver cirrhosis. Cor et Vasa, 2013.

55(4): p. e391-e396.

7. Licata, A., et al., Clinical implications of the hyperdynamic syndrome in cirrhosis. Eur J Intern Med, 2014. 25(9): p. 795-802.

8. Rugarli, C., RUGARLI Medicina interna sistematica. 2015: Edra.

9. Zardi, E.M., et al., Cirrhotic cardiomyopathy in the pre- and post-liver transplantation phase. J Cardiol, 2016. 67(2): p. 125-30.

10. Páll, A., et al., Pathophysiological and clinical approach to cirrhotic cardiomyopathy. Journal of Gastrointestinal and Liver Diseases, 2014. 23(3): p. 301-310.

11. Al-Busafi, S.A., et al., Clinical Manifestations of Portal Hypertension. International Journal of Hepatology, 2012. 2012: p. 203794.

12. Yang, Y.Y. and H.C. Lin, The heart: pathophysiology and clinical implications of cirrhotic cardiomyopathy. J Chin Med Assoc, 2012. 75(12): p. 619-23.

13. Møller Sø Fau - Møller, S., J.H. Henriksen Jh Fau - Henriksen, and F. Bendtsen F Fau - Bendtsen, Extrahepatic complications to cirrhosis and portal hypertension: Haemodynamic and homeostatic aspects. (1007-9327 (Print)).

14. Møller, S. and J.H. Henriksen, Cardiopulmonary complications to chronic liver disease. World J Gastroent, 2006. 12(4): p. 526-538.

15. Fede, G., et al., Cardiovascular dysfunction in patients with liver cirrhosis. Annals of Gastroenterology : Quarterly Publication of the Hellenic Society of Gastroenterology, 2015. 28(1): p. 31-40.

16. Ruiz-del-Árbol, L. and R. Serradilla, Cirrhotic cardiomyopathy. World journal of gastroenterology, 2015. 21(41): p. 11502.

17. Wong, F., Cirrhotic cardiomyopathy. Hepatol Int, 2009. 3(1): p. 294-304.

18. Pacher, P., S. Bátkai, and G. Kunos, Cirrhotic cardiomyopathy: an endocannabinoid connection? British journal of pharmacology, 2005. 146(3): p. 313-314.

19. Liu, H., S.A. Gaskari, and S.S. Lee, Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World journal of gastroenterology, 2006. 12(6): p. 837.

20. Lentine, K.L., et al., Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association and the American College of Cardiology Foundation. Circulation, 2012. 126(5): p. 617-663.

21. Shah, N., et al., Hepatorenal syndrome. Disease-a-Month.

22. Surani, S.R., et al., Pulmonary complications of hepatic diseases. World Journal of Gastroenterology, 2016. 22(26): p. 6008-6015.

23. Lee, R.F., T.K. Glenn, and S.S. Lee, Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol, 2007. 21(1): p. 125-40.

24. Moller, S., et al., New insights into cirrhotic cardiomyopathy. Int J Cardiol, 2013.

167(4): p. 1101-8.

25. Sattarzadeh-Badkoubeh, R., et al., Evaluation of Cardiac Systolic Function in Cirrhotic Patients Undergoing Liver Transplantation. Acta Medica Iranica, 2015.

53(8): p. 476-481.

26. Somani, P.O., et al., Diastolic dysfunction characterizes cirrhotic cardiomyopathy. Indian Heart J, 2014. 66(6): p. 649-55.

27. Kazankov, K., et al., Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver International, 2011. 31(4): p. 534-540.

28. Møller, S. and J.H. Henriksen, Cirrhotic cardiomyopathy. Journal of hepatology, 2010. 53(1): p. 179-190.

29. Karagiannakis, D.S., et al., Diastolic cardiac dysfunction is a predictor of dismal prognosis in patients with liver cirrhosis. Hepatology international, 2014. 8(4): p. 588-594.

30. Mozos, I., Arrhythmia risk in liver cirrhosis. World Journal of Hepatology, 2015.

7(4): p. 662-672.

31. Nazar, A., et al., LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. Journal of hepatology, 2013. 58(1): p. 51-57.

32. Timoh, T., et al., A perspective on cirrhotic cardiomyopathy. Transplant Proc, 2011. 43(5): p. 1649-53.

33. Josefsson, A., et al., Prevalence of pre-transplant electrocardiographic abnormalities and post-transplant cardiac events in patients with liver cirrhosis. BMC gastroenterology, 2014. 14(1): p. 1.

34. Pimenta, J., et al., B‐type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis. Liver International, 2010. 30(7): p. 1059-1066.

35. Henriksen, J.H., et al., Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut, 2003. 52(10): p. 1511-1517.

36. Saner, F.H., et al., High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. Transpl Int, 2011. 24(5): p. 425- 32.

37. Milani, A., et al., Cirrhotic cardiomyopathy. Dig Liver Dis, 2007. 39(6): p. 507- 15.

38. Garg, A. and W.F. Armstrong, Echocardiography in liver transplant candidates. JACC: Cardiovascular Imaging, 2013. 6(1): p. 105-119.

39. Sampaio, F., et al., Systolic and diastolic dysfunction in cirrhosis: a tissue‐ Doppler and speckle tracking echocardiography study. Liver International, 2013. 33(8): p. 1158-1165.

40. Kim, M.Y., et al., Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis. Korean J Hepatol, 2010. 16(4): p. 376-82.

41. Barbosa, M., et al., Cirrhotic cardiomyopathy: Isn't stress evaluation always required for the diagnosis? World J Hepatol, 2016. 8(3): p. 200-6.

42. Grancea-Iancu, V.L.M., Cirrhotic cardiomyopathy. Journal of medicine and life, 2014. 7(Spec Iss 3): p. 53.

43. Li, X., et al., Cirrhosis-related changes in left ventricular function and correlation with the model for end-stage liver disease score. Int J Clin Exp Med, 2014. 7(12): p. 5751-5757.

44. Møller, S. and J.H. Henriksen, Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart, 2002. 87(1): p. 9-15. 45. Mandell, M.S., et al., Cardiac evaluation of liver transplant candidates. World

Journal of Gastroenterology : WJG, 2008. 14(22): p. 3445-3451.

46. Farr, M. and P.C. Schulze, Recent advances in the diagnosis and management of cirrhosis-associated cardiomyopathy in liver transplant candidates: advanced echo imaging, cardiac biomarkers, and advanced heart failure therapies. Clin Med Insights Cardiol, 2014. 8(Suppl 1): p. 67-74.

47. Raval, Z., et al., Cardiovascular risk assessment of the liver transplant candidate. Journal of the American College of Cardiology, 2011. 58(3): p. 223-231.

48. Diedrich, D.A., et al. Influence of coronary artery disease on outcomes after liver transplantation. Elsevier.

49. Sehgal, L., et al., Preoperative cardiovascular investigations in liver transplant candidate: An update. Indian Journal of Anaesthesia, 2016. 60(1): p. 12-18. 50. Harinstein, M.E., et al., Role of baseline echocardiography in the preoperative

management of liver transplant candidates. The American journal of cardiology, 2012. 110(12): p. 1852-1855.

51. Ripoll, C., et al., The heart in liver transplantation. J Hepatol, 2011. 54(4): p. 810-22.

52. Baik, S.K., T.R. Fouad, and S.S. Lee, Cirrhotic cardiomyopathy. Orphanet J Rare Dis, 2007. 2: p. 15.

53. Chen, Y., et al., A detailed evaluation of cardiac function in cirrhotic patients and its alteration with or without liver transplantation. Journal of Cardiology, 2016.

54. Wroński, J., et al., Retrospective analysis of liver cirrhosis influence on heart walls thickness. Pathology - Research and Practice, 2015. 211(2): p. 145-149. 55. Merli, M., et al., Cardiac dysfunction in cirrhosis is not associated with the

severity of liver disease. European Journal of Internal Medicine, 2013. 24(2): p. 172-176.

56. Rahman, S. and S.V. Mallett, Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients. World J Hepatol, 2015.

7(3): p. 507-520.

57. Sonny, A., et al., Impact and persistence of cirrhotic cardiomyopathy after liver transplantation. Clinical Transplantation, 2016. 30(9): p. 986-993.